ANX1502 tablet shows promise in proof-of-concept CAD trial
Annexon Biosciences’ new tablet formulation of its experimental therapy ANX1502 reduced key clinical and biomarker measures in the three cold agglutinin disease (CAD) patients so far enrolled in a proof-of-concept clinical trial. “In patients treated with the oral small molecule ANX1502, we are encouraged by the changes in…